Sigma Planning Corp Decreases Stock Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Posted by on Feb 24th, 2023

Sigma Planning Corp cut its stake in Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) by 9.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,387 shares of the company’s stock after selling 928 shares during the period. Sigma Planning Corp’s holdings in Reata Pharmaceuticals were worth $236,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can acquired a new stake in shares of Reata Pharmaceuticals during the third quarter worth $38,000. US Bancorp DE grew its position in Reata Pharmaceuticals by 930.5% in the 1st quarter. US Bancorp DE now owns 1,824 shares of the company’s stock valued at $60,000 after buying an additional 1,647 shares in the last quarter. UBS Group AG boosted its position in shares of Reata Pharmaceuticals by 42.2% during the 2nd quarter. UBS Group AG now owns 2,558 shares of the company’s stock valued at $78,000 after purchasing an additional 759 shares in the last quarter. Macquarie Group Ltd. boosted its position in shares of Reata Pharmaceuticals by 51.1% during the 2nd quarter. Macquarie Group Ltd. now owns 2,768 shares of the company’s stock valued at $84,000 after purchasing an additional 936 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Reata Pharmaceuticals by 176.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 2,881 shares of the company’s stock valued at $72,000 after purchasing an additional 1,840 shares in the last quarter. 76.13% of the stock is owned by institutional investors and hedge funds.

Reata Pharmaceuticals Price Performance

Shares of RETA stock opened at $50.45 on Friday. The stock has a market cap of $1.85 billion, a PE ratio of -5.89 and a beta of 1.25. The stock has a 50-day moving average of $40.85 and a 200-day moving average of $33.66. Reata Pharmaceuticals, Inc. has a one year low of $18.47 and a one year high of $51.98.

Analysts Set New Price Targets

Several analysts recently commented on RETA shares. Citigroup raised their price target on shares of Reata Pharmaceuticals from $51.00 to $53.00 and gave the stock a “buy” rating in a report on Wednesday, November 9th. Barclays boosted their price target on shares of Reata Pharmaceuticals from $43.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, November 9th. The Goldman Sachs Group boosted their target price on shares of Reata Pharmaceuticals from $86.00 to $115.00 and gave the company a “buy” rating in a research note on Monday, November 28th. Finally, Robert W. Baird boosted their target price on shares of Reata Pharmaceuticals to $40.00 in a research note on Tuesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $66.67.

About Reata Pharmaceuticals

(Get Rating)

Reata Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

Read More

Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating).

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.